text stringlengths 377 3.32k |
|---|
{"timestamp": "2025-07-18 11:59:09.482", "mode": "azero-full", "language": "en", "target": "en", "text": "such as sedation and impulse control.", "text_tts": "and impulse control", "translate": "such as sedation and impulse control.", "translate_tts": "such as sedation and impulse control", "is_final": false, "emotion"... |
{"timestamp": "2025-07-18 11:59:24.591", "mode": "azero-full", "language": "en", "target": "en", "text": "Tevapadon could potentially be used as a monotherapy for early Parkinson's disease as well as an adjunctive therapy to levodopa for more advanced patients, which would be a complementary addition to our existing PD... |
{"timestamp": "2025-07-18 11:59:31.586", "mode": "azero-full", "language": "en", "target": "en", "text": "We expect to submit to Vapadon for regulatory review later this year with commercialization expected in twenty twenty six.", "text_tts": "ed in twenty twenty six", "translate": "We expect to submit to Vapadon for r... |
{"timestamp": "2025-07-18 11:59:39.656", "mode": "azero-full", "language": "en", "target": "en", "text": "Overall, I'm extremely pleased with the execution and strong momentum across our commercial portfolio.", "text_tts": "portfolio", "translate": "Overall, I'm extremely pleased with the execution and strong momentum ... |
{"timestamp": "2025-07-18 11:59:44.341", "mode": "azero-full", "language": "en", "target": "en", "text": "And with that, I'll turn the call over to Rupal for comments on our R and D highlights. Rupal?", "text_tts": "comments on our R and D highlights Rupal", "translate": "And with that, I'll turn the call over to Rupal... |
{"timestamp": "2025-07-18 11:59:48.322", "mode": "azero-full", "language": "en", "target": "en", "text": "Thank you, Jeff. I will start with immunology.", "text_tts": "I will start with immunology", "translate": "Thank you, Jeff. I will start with immunology.", "translate_tts": "Thank you Jeff I will start with immunol... |
{"timestamp": "2025-07-18 11:59:52.439", "mode": "azero-full", "language": "en", "target": "en", "text": "we received European approval for RINVOK and GCA,", "text_tts": "approval for RINVOK and GCA", "translate": "we received European approval for RINVOK and GCA,", "translate_tts": "we received European approval for R... |
{"timestamp": "2025-07-18 11:59:54.131", "mode": "azero-full", "language": "en", "target": "en", "text": "and expect FDA approval soon.", "text_tts": "approval soon", "translate": "and expect FDA approval soon.", "translate_tts": "and expect FDA approval soon", "is_final": false, "emotion": "", "events": "📞🌠", "think... |
{"timestamp": "2025-07-18 12:00:00.225", "mode": "azero-full", "language": "en", "target": "en", "text": "We remain on track for several important data readouts this year as well, including", "text_tts": "s this year as well including", "translate": "We remain on track for several important data readouts this year as w... |
{"timestamp": "2025-07-18 12:00:04.770", "mode": "azero-full", "language": "en", "target": "en", "text": "Phase three data for RENVOC in Alopecia Ariada and Viniligo.", "text_tts": "for RENVOC in Alopecia Ariada and Viniligo", "translate": "Phase three data for RENVOC in Alopecia Ariada and Viniligo.", "translate_tts":... |
{"timestamp": "2025-07-18 12:00:10.394", "mode": "azero-full", "language": "en", "target": "en", "text": "and data from SKYRIZZI's head to head study in psoriasis versus SOTIC two.", "text_tts": "y in psoriasis versus SOTIC two", "translate": "and data from SKYRIZZI's head to head study in psoriasis versus SOTIC two.",... |
{"timestamp": "2025-07-18 12:00:17.897", "mode": "azero-full", "language": "en", "target": "en", "text": "Our early and mid stage immunology pipeline continues to advance. Recent initiations include", "text_tts": "to advance Recent initiations include", "translate": "Our early and mid stage immunology pipeline continue... |
{"timestamp": "2025-07-18 12:00:25.562", "mode": "azero-full", "language": "en", "target": "en", "text": "a Phase two study evaluating SKYRIZI in combination with lutekizumab in psoriatic arthritis.", "text_tts": "tekizumab in psoriatic arthritis", "translate": "a Phase two study evaluating SKYRIZI in combination with ... |
{"timestamp": "2025-07-18 12:00:35.382", "mode": "azero-full", "language": "en", "target": "en", "text": "and a Phase I study for our next generation TL one A antibody, which is designed to have less frequent dosing compared to other TL one As in development.", "text_tts": "er TL one As in development", "translate": "a... |
{"timestamp": "2025-07-18 12:00:42.177", "mode": "azero-full", "language": "en", "target": "en", "text": "and will be evaluated in combination with SKYRIZZI in both Crohn's disease and ulcerative colitis.", "text_tts": "is", "translate": "and will be evaluated in combination with SKYRIZZI in both Crohn's disease and ul... |
{"timestamp": "2025-07-18 12:00:54.174", "mode": "azero-full", "language": "en", "target": "en", "text": "This summer, we will start a Phase two study evaluating a combination of lutecizumab and our anti CD forty gravagalimab in rheumatoid arthritis.", "text_tts": "in rheumatoid arthritis", "translate": "This summer, w... |
{"timestamp": "2025-07-18 12:00:57.277", "mode": "azero-full", "language": "en", "target": "en", "text": "Moving to our ADCs and oncology.", "text_tts": "r ADCs and oncology", "translate": "Moving to our ADCs and oncology.", "translate_tts": "Moving to our ADCs and oncology", "is_final": false, "emotion": "", "events":... |
{"timestamp": "2025-07-18 12:01:09.383", "mode": "azero-full", "language": "en", "target": "en", "text": "We anticipate accelerated approval in the second quarter for TelisoV as a monotherapy in previously treated nonsquamous non small cell lung cancer with high CMET expression.", "text_tts": "expression", "translate":... |
{"timestamp": "2025-07-18 12:01:14.071", "mode": "azero-full", "language": "en", "target": "en", "text": "This is a segment of lung cancer with high unmet need, and when approved,", "text_tts": "and when approved", "translate": "This is a segment of lung cancer with high unmet need, and when approved,", "translate_tts"... |
{"timestamp": "2025-07-18 12:01:19.145", "mode": "azero-full", "language": "en", "target": "en", "text": "TelisoV will be the first CMET directed ADC for these patients.", "text_tts": "or these patients", "translate": "TelisoV will be the first CMET directed ADC for these patients.", "translate_tts": "TelisoV will be t... |
{"timestamp": "2025-07-18 12:01:25.850", "mode": "azero-full", "language": "en", "target": "en", "text": "We're also making good progress with TMAB A, our next generation CMET ADC.", "text_tts": "eneration CMET ADC", "translate": "We're also making good progress with TMAB A, our next generation CMET ADC.", "translate_t... |
{"timestamp": "2025-07-18 12:01:31.392", "mode": "azero-full", "language": "en", "target": "en", "text": "a Phase two dose optimization study evaluating TMABA with a PD one inhibitor", "text_tts": "with a PD one inhibitor", "translate": "a Phase two dose optimization study evaluating TMABA with a PD one inhibitor", "tr... |
{"timestamp": "2025-07-18 12:01:39.976", "mode": "azero-full", "language": "en", "target": "en", "text": "as a frontline combination therapy in EGFR wild type non small cell lung cancer was recently initiated.", "text_tts": "recently initiated", "translate": "as a frontline combination therapy in EGFR wild type non sma... |
{"timestamp": "2025-07-18 12:01:42.615", "mode": "azero-full", "language": "en", "target": "en", "text": "in the EGFR immune segment.", "text_tts": "GFR immune segment", "translate": "in the EGFR immune segment.", "translate_tts": "in the EGFR immune segment", "is_final": false, "emotion": "", "events": "📞🌠🏠🔊💬👂",... |
{"timestamp": "2025-07-18 12:01:52.196", "mode": "azero-full", "language": "en", "target": "en", "text": "We plan to initiate studies for TMAB A as a monotherapy in the second line setting and in combination with osimertinib in the first line setting.", "text_tts": "ib in the first line setting", "translate": "We plan ... |
{"timestamp": "2025-07-18 12:01:57.423", "mode": "azero-full", "language": "en", "target": "en", "text": "Preliminary Phase I results will be presented at the upcoming ASCO meeting.", "text_tts": "upcoming ASCO meeting", "translate": "Preliminary Phase I results will be presented at the upcoming ASCO meeting.", "transl... |
{"timestamp": "2025-07-18 12:02:05.408", "mode": "azero-full", "language": "en", "target": "en", "text": "This year, Phase two data from our CRC study evaluating TMAB A in combination with bevacizumab will be available.", "text_tts": "bevacizumab will be available", "translate": "This year, Phase two data from our CRC ... |
{"timestamp": "2025-07-18 12:02:10.430", "mode": "azero-full", "language": "en", "target": "en", "text": "which could enable a Phase three study in an all comers population.", "text_tts": "an all comers population", "translate": "which could enable a Phase three study in an all comers population.", "translate_tts": "wh... |
{"timestamp": "2025-07-18 12:02:18.259", "mode": "azero-full", "language": "en", "target": "en", "text": "Progress also continues with ABBV seven hundred six in small cell lung cancer.", "text_tts": "in small cell lung cancer", "translate": "Progress also continues with ABBV seven hundred six in small cell lung cancer.... |
{"timestamp": "2025-07-18 12:02:18.633", "mode": "azero-full", "language": "en", "target": "en", "text": "Recall.", "text_tts": "Recall", "translate": "Recall.", "translate_tts": "Recall", "is_final": false, "emotion": "", "events": "📞🌠🏠🔊", "think": "", "wav_name": "b5a761d0-948a-426e-8830-3ec3bd6c7e1c", "embedding... |
{"timestamp": "2025-07-18 12:02:25.622", "mode": "azero-full", "language": "en", "target": "en", "text": "this ADC utilizes the same TOPO warhead and linker technology as TMAB A.", "text_tts": "head and linker technology as TMAB A", "translate": "this ADC utilizes the same TOPO warhead and linker technology as TMAB A."... |
{"timestamp": "2025-07-18 12:02:28.270", "mode": "azero-full", "language": "en", "target": "en", "text": "but with an antibody that targets SET six.", "text_tts": "antibody that targets SET six", "translate": "but with an antibody that targets SET six.", "translate_tts": "but with an antibody that targets SET six", "is... |
{"timestamp": "2025-07-18 12:02:30.759", "mode": "azero-full", "language": "en", "target": "en", "text": "in the Phase I study,", "text_tts": "I study", "translate": "in the Phase I study,", "translate_tts": "in the Phase I study", "is_final": false, "emotion": "", "events": "📞🌠🏠🔊", "think": "", "wav_name": "b5a761... |
{"timestamp": "2025-07-18 12:02:34.113", "mode": "azero-full", "language": "en", "target": "en", "text": "seven hundred and six was efficacious across doses,", "text_tts": "en hundred and six was efficacious across doses", "translate": "seven hundred and six was efficacious across doses,", "translate_tts": "seven hundr... |
{"timestamp": "2025-07-18 12:02:42.226", "mode": "azero-full", "language": "en", "target": "en", "text": "with an objective response rate of approximately sixty percent in patients with relapsed or refractory small cell lung cancer.", "text_tts": "ractory small cell lung cancer", "translate": "with an objective respons... |
{"timestamp": "2025-07-18 12:02:56.908", "mode": "azero-full", "language": "en", "target": "en", "text": "Based on maturing duration of response and progression free survival data, we plan to advance seven hundred and six into a trial in a relapsed refractory population and a dose optimization study in combination", "t... |
{"timestamp": "2025-07-18 12:02:59.442", "mode": "azero-full", "language": "en", "target": "en", "text": "With a PDL one in the front line,", "text_tts": "PDL one in the front line", "translate": "With a PDL one in the front line,", "translate_tts": "With a PDL one in the front line", "is_final": false, "emotion": "", ... |
{"timestamp": "2025-07-18 12:03:02.067", "mode": "azero-full", "language": "en", "target": "en", "text": "with the goal of establishing", "text_tts": "of establishing", "translate": "with the goal of establishing", "translate_tts": "with the goal of establishing", "is_final": false, "emotion": "", "events": "📞🌠👨📯",... |
{"timestamp": "2025-07-18 12:03:06.098", "mode": "azero-full", "language": "en", "target": "en", "text": "a chemo sparing regimen as a new standard of care.", "text_tts": "f care", "translate": "a chemo sparing regimen as a new standard of care.", "translate_tts": "a chemo sparing regimen as a new standard of care", "i... |
{"timestamp": "2025-07-18 12:03:10.006", "mode": "azero-full", "language": "en", "target": "en", "text": "In the area of hematologic oncology,", "text_tts": "hematologic oncology", "translate": "In the area of hematologic oncology,", "translate_tts": "In the area of hematologic oncology", "is_final": false, "emotion": ... |
{"timestamp": "2025-07-18 12:03:15.778", "mode": "azero-full", "language": "en", "target": "en", "text": "The data readout remains on track for the Phase three VENCLEXTA MDS trial.", "text_tts": "three VENCLEXTA MDS trial", "translate": "The data readout remains on track for the Phase three VENCLEXTA MDS trial.", "tran... |
{"timestamp": "2025-07-18 12:03:17.256", "mode": "azero-full", "language": "en", "target": "en", "text": "And if positive,", "text_tts": "And if positive", "translate": "And if positive,", "translate_tts": "And if positive", "is_final": false, "emotion": "😊", "events": "📞🌠🏠🔊", "think": "", "wav_name": "b5a761d0-94... |
{"timestamp": "2025-07-18 12:03:20.023", "mode": "azero-full", "language": "en", "target": "en", "text": "our regulatory submissions would follow later in the year.", "text_tts": "ry submissions would follow later in the year", "translate": "our regulatory submissions would follow later in the year.", "translate_tts": ... |
{"timestamp": "2025-07-18 12:03:26.104", "mode": "azero-full", "language": "en", "target": "en", "text": "A regulatory submission for PIVEC and BPDCN is also planned for this year.", "text_tts": "PDCN is also planned for this year", "translate": "A regulatory submission for PIVEC and BPDCN is also planned for this year... |
{"timestamp": "2025-07-18 12:03:36.292", "mode": "azero-full", "language": "en", "target": "en", "text": "We continue to make good progress with our BCMA CD three bispecific, ABBV three hundred and eighty three in multiple myeloma.", "text_tts": "BBV three hundred and eighty three in multiple myeloma", "translate": "We... |
{"timestamp": "2025-07-18 12:03:45.267", "mode": "azero-full", "language": "en", "target": "en", "text": "Recruitment is going well in the Phase three monotherapy study in later lines, and we are on track to be fully enrolled by early next year.", "text_tts": "ly enrolled by early next year", "translate": "Recruitment ... |
{"timestamp": "2025-07-18 12:03:50.831", "mode": "azero-full", "language": "en", "target": "en", "text": "Additionally, we continue to evaluate three hundred and eighty three in various combinations.", "text_tts": "and eighty three in various combinations", "translate": "Additionally, we continue to evaluate three hund... |
{"timestamp": "2025-07-18 12:03:54.563", "mode": "azero-full", "language": "en", "target": "en", "text": "including with POMILIST, REVLIMID, DARZALEX", "text_tts": "POMILIST REVLIMID DARZALEX", "translate": "including with POMILIST, REVLIMID, DARZALEX", "translate_tts": "including with POMILIST REVLIMID DARZALEX", "is_... |
{"timestamp": "2025-07-18 12:03:55.258", "mode": "azero-full", "language": "en", "target": "en", "text": "and Iberdamind.", "text_tts": "and Iberdamind", "translate": "and Iberdamind.", "translate_tts": "and Iberdamind", "is_final": false, "emotion": "", "events": "📞🌠👨📯", "think": "", "wav_name": "b5a761d0-948a-426... |
{"timestamp": "2025-07-18 12:03:59.375", "mode": "azero-full", "language": "en", "target": "en", "text": "We'll begin seeing data from these combinations next year.", "text_tts": "data from these combinations next year", "translate": "We'll begin seeing data from these combinations next year.", "translate_tts": "Well b... |
{"timestamp": "2025-07-18 12:04:03.262", "mode": "azero-full", "language": "en", "target": "en", "text": "which could enable Phase three studies in earlier lines of therapy.", "text_tts": "Phase three studies in earlier lines of therapy", "translate": "which could enable Phase three studies in earlier lines of therapy.... |
{"timestamp": "2025-07-18 12:04:06.834", "mode": "azero-full", "language": "en", "target": "en", "text": "Now moving to neuroscience.", "text_tts": "science", "translate": "Now moving to neuroscience.", "translate_tts": "Now moving to neuroscience", "is_final": false, "emotion": "", "events": "📞👂👨📯🏠🔊", "think": "... |
{"timestamp": "2025-07-18 12:04:15.205", "mode": "azero-full", "language": "en", "target": "en", "text": "Theorem data from the long term Tempo four Phase three study continue to support Tevapidon's favorable benefit risk profile.", "text_tts": "port Tevapidons favorable benefit risk profile", "translate": "Theorem dat... |
{"timestamp": "2025-07-18 12:04:21.562", "mode": "azero-full", "language": "en", "target": "en", "text": "Efficacy in both early and advanced Parkinson's patients was maintained beyond the year", "text_tts": "s patients was maintained beyond the year", "translate": "Efficacy in both early and advanced Parkinson's patie... |
{"timestamp": "2025-07-18 12:04:30.996", "mode": "azero-full", "language": "en", "target": "en", "text": "and the safety profile was consistent with that observed in the previous Phase three studies with no new safety concerns identified.", "text_tts": "with no new safety concerns identified", "translate": "and the saf... |
{"timestamp": "2025-07-18 12:04:35.833", "mode": "azero-full", "language": "en", "target": "en", "text": "Rates of adverse events of special interest remain low.", "text_tts": "adverse events of special interest remain low", "translate": "Rates of adverse events of special interest remain low.", "translate_tts": "Rates... |
{"timestamp": "2025-07-18 12:04:40.714", "mode": "azero-full", "language": "en", "target": "en", "text": "with impulse control disorder and peripheral edema less than one percent.", "text_tts": "than one percent", "translate": "with impulse control disorder and peripheral edema less than one percent.", "translate_tts":... |
{"timestamp": "2025-07-18 12:04:43.977", "mode": "azero-full", "language": "en", "target": "en", "text": "dyskinesia, approximately two percent.", "text_tts": "approximately two percent", "translate": "dyskinesia, approximately two percent.", "translate_tts": "dyskinesia approximately two percent", "is_final": false, "... |
{"timestamp": "2025-07-18 12:04:45.980", "mode": "azero-full", "language": "en", "target": "en", "text": "and sedation less than five percent.", "text_tts": "n less than five percent", "translate": "and sedation less than five percent.", "translate_tts": "and sedation less than five percent", "is_final": false, "emotio... |
{"timestamp": "2025-07-18 12:04:54.309", "mode": "azero-full", "language": "en", "target": "en", "text": "These results underscore Tevapadon's potential to become an important new treatment option for patients with Parkinson's disease.", "text_tts": "ith Parkinsons disease", "translate": "These results underscore Tevap... |
{"timestamp": "2025-07-18 12:04:57.555", "mode": "azero-full", "language": "en", "target": "en", "text": "Our regulatory application is planned for later in the year.", "text_tts": "application is planned for later in the year", "translate": "Our regulatory application is planned for later in the year.", "translate_tts... |
{"timestamp": "2025-07-18 12:05:01.299", "mode": "azero-full", "language": "en", "target": "en", "text": "Moving to other areas of our pipeline.", "text_tts": "areas of our pipeline", "translate": "Moving to other areas of our pipeline.", "translate_tts": "Moving to other areas of our pipeline", "is_final": false, "emo... |
{"timestamp": "2025-07-18 12:05:09.154", "mode": "azero-full", "language": "en", "target": "en", "text": "In aesthetics, the regulatory application for a rapid onset short acting toxin Bonti was recently submitted.", "text_tts": "submitted", "translate": "In aesthetics, the regulatory application for a rapid onset shor... |
{"timestamp": "2025-07-18 12:05:15.722", "mode": "azero-full", "language": "en", "target": "en", "text": "We also began the clinical program to evaluate co administration of Bonti and Botox.", "text_tts": "of Bonti and Botox", "translate": "We also began the clinical program to evaluate co administration of Bonti and B... |
{"timestamp": "2025-07-18 12:05:20.532", "mode": "azero-full", "language": "en", "target": "en", "text": "which has the potential to be co formulated as a novel product.", "text_tts": "a novel product", "translate": "which has the potential to be co formulated as a novel product.", "translate_tts": "which has the poten... |
{"timestamp": "2025-07-18 12:05:26.283", "mode": "azero-full", "language": "en", "target": "en", "text": "offering the combined benefits of rapid onset and Botox light duration.", "text_tts": "x light duration", "translate": "offering the combined benefits of rapid onset and Botox light duration.", "translate_tts": "of... |
{"timestamp": "2025-07-18 12:05:28.837", "mode": "azero-full", "language": "en", "target": "en", "text": "in obesity.", "text_tts": "in obesity", "translate": "in obesity.", "translate_tts": "in obesity", "is_final": false, "emotion": "😮", "events": "📞🌠💬👂", "think": "", "wav_name": "b5a761d0-948a-426e-8830-3ec3bd6... |
{"timestamp": "2025-07-18 12:05:34.018", "mode": "azero-full", "language": "en", "target": "en", "text": "Our partner, Gubra, recently announced positive interim results from the first part", "text_tts": "first part", "translate": "Our partner, Gubra, recently announced positive interim results from the first part", "t... |
{"timestamp": "2025-07-18 12:05:41.860", "mode": "azero-full", "language": "en", "target": "en", "text": "of a multiple ascending dose study for our long acting amylin analog, ABBV two hundred ninety five.", "text_tts": "two hundred ninety five", "translate": "of a multiple ascending dose study for our long acting amyl... |
{"timestamp": "2025-07-18 12:05:51.688", "mode": "azero-full", "language": "en", "target": "en", "text": "This initial phase of the study tested one and two milligrams, dosed once weekly for six weeks in healthy, lean and overweight patients.", "text_tts": "verweight patients", "translate": "This initial phase of the s... |
{"timestamp": "2025-07-18 12:05:54.616", "mode": "azero-full", "language": "en", "target": "en", "text": "The study showed two hundred and ninety five performed well.", "text_tts": "two hundred and ninety five performed well", "translate": "The study showed two hundred and ninety five performed well.", "translate_tts":... |
{"timestamp": "2025-07-18 12:06:05.848", "mode": "azero-full", "language": "en", "target": "en", "text": "demonstrating a dose dependent mean weight loss compared to placebo and a tolerability profile consistent with the results from the single ascending dose study.", "text_tts": "e single ascending dose study", "trans... |
{"timestamp": "2025-07-18 12:06:08.691", "mode": "azero-full", "language": "en", "target": "en", "text": "mean weight loss in the two milligram cohort,", "text_tts": "loss in the two milligram cohort", "translate": "mean weight loss in the two milligram cohort,", "translate_tts": "mean weight loss in the two milligram ... |
{"timestamp": "2025-07-18 12:06:12.194", "mode": "azero-full", "language": "en", "target": "en", "text": "which had a mean BMI of twenty four,", "text_tts": "a mean BMI of twenty four", "translate": "which had a mean BMI of twenty four,", "translate_tts": "which had a mean BMI of twenty four", "is_final": false, "emoti... |
{"timestamp": "2025-07-18 12:06:13.797", "mode": "azero-full", "language": "en", "target": "en", "text": "was seven point eight percent.", "text_tts": "even point eight percent", "translate": "was seven point eight percent.", "translate_tts": "was seven point eight percent", "is_final": false, "emotion": "", "events": ... |
{"timestamp": "2025-07-18 12:06:17.808", "mode": "azero-full", "language": "en", "target": "en", "text": "Compared to a weight gain of two percent in the placebo arm,", "text_tts": "in the placebo arm", "translate": "Compared to a weight gain of two percent in the placebo arm,", "translate_tts": "Compared to a weight g... |
{"timestamp": "2025-07-18 12:06:19.185", "mode": "azero-full", "language": "en", "target": "en", "text": "on day forty three.", "text_tts": "on day forty three", "translate": "on day forty three.", "translate_tts": "on day forty three", "is_final": false, "emotion": "", "events": "📞🌠👨📯", "think": "", "wav_name": "b... |
{"timestamp": "2025-07-18 12:06:27.275", "mode": "azero-full", "language": "en", "target": "en", "text": "The second phase of this study is ongoing and is evaluating higher doses in overweight and obese patients,", "text_tts": "rweight and obese patients", "translate": "The second phase of this study is ongoing and is ... |
{"timestamp": "2025-07-18 12:06:28.897", "mode": "azero-full", "language": "en", "target": "en", "text": "with twelve week dosing.", "text_tts": "elve week dosing", "translate": "with twelve week dosing.", "translate_tts": "with twelve week dosing", "is_final": false, "emotion": "", "events": "📞🌠👨📯🏠🔊", "think": "... |
{"timestamp": "2025-07-18 12:06:33.573", "mode": "azero-full", "language": "en", "target": "en", "text": "Titration and longer dosing intervals will also be assessed.", "text_tts": "longer dosing intervals will also be assessed", "translate": "Titration and longer dosing intervals will also be assessed.", "translate_tt... |
{"timestamp": "2025-07-18 12:06:34.560", "mode": "azero-full", "language": "en", "target": "en", "text": "full data,", "text_tts": "full data", "translate": "full data,", "translate_tts": "full data", "is_final": false, "emotion": "😮", "events": "📞👂", "think": "", "wav_name": "b5a761d0-948a-426e-8830-3ec3bd6c7e1c", ... |
{"timestamp": "2025-07-18 12:06:38.404", "mode": "azero-full", "language": "en", "target": "en", "text": "from this part of the study are expected next year.", "text_tts": "the study are expected next year", "translate": "from this part of the study are expected next year.", "translate_tts": "from this part of the stud... |
{"timestamp": "2025-07-18 12:06:43.648", "mode": "azero-full", "language": "en", "target": "en", "text": "To summarize, significant progress continues with our pipeline.", "text_tts": "progress continues with our pipeline", "translate": "To summarize, significant progress continues with our pipeline.", "translate_tts":... |
{"timestamp": "2025-07-18 12:06:46.346", "mode": "azero-full", "language": "en", "target": "en", "text": "and we look forward to important data readouts.", "text_tts": "to important data readouts", "translate": "and we look forward to important data readouts.", "translate_tts": "and we look forward to important data re... |
{"timestamp": "2025-07-18 12:06:50.969", "mode": "azero-full", "language": "en", "target": "en", "text": "regulatory submissions and approvals throughout twenty twenty five.", "text_tts": "submissions and approvals throughout twenty twenty five", "translate": "regulatory submissions and approvals throughout twenty twen... |
{"timestamp": "2025-07-18 12:06:55.173", "mode": "azero-full", "language": "en", "target": "en", "text": "With that, I'll turn the call over to Scott.", "text_tts": "ll turn the call over to Scott", "translate": "With that, I'll turn the call over to Scott.", "translate_tts": "With that Ill turn the call over to Scott"... |
{"timestamp": "2025-07-18 12:06:57.651", "mode": "azero-full", "language": "en", "target": "en", "text": "Thank you, Rupal.", "text_tts": "Thank you Rupal", "translate": "Thank you, Rupal.", "translate_tts": "Thank you Rupal", "is_final": false, "emotion": "😊", "events": "📞🌠🏠🔊", "think": "", "wav_name": "b5a761d0-... |
{"timestamp": "2025-07-18 12:07:00.289", "mode": "azero-full", "language": "en", "target": "en", "text": "Starting with our first quarter results.", "text_tts": "quarter results", "translate": "Starting with our first quarter results.", "translate_tts": "Starting with our first quarter results", "is_final": false, "emo... |
{"timestamp": "2025-07-18 12:07:04.857", "mode": "azero-full", "language": "en", "target": "en", "text": "we reported adjusted earnings per share of two dollars forty six cents.", "text_tts": "wo dollars forty six cents", "translate": "we reported adjusted earnings per share of two dollars forty six cents.", "translate... |
{"timestamp": "2025-07-18 12:07:08.256", "mode": "azero-full", "language": "en", "target": "en", "text": "which is ten cents above our guidance midpoint.", "text_tts": "s above our guidance midpoint", "translate": "which is ten cents above our guidance midpoint.", "translate_tts": "which is ten cents above our guidance... |
{"timestamp": "2025-07-18 12:07:15.161", "mode": "azero-full", "language": "en", "target": "en", "text": "These results include a thirteen percent unfavorable impact from acquired IPR and D expense.", "text_tts": "le impact from acquired IPR and D expense", "translate": "These results include a thirteen percent unfavor... |
{"timestamp": "2025-07-18 12:07:24.577", "mode": "azero-full", "language": "en", "target": "en", "text": "Total net revenues were more than thirteen point three billion dollars, reflecting robust growth of nine point eight percent on an operational basis.", "text_tts": "eight percent on an operational basis", "translat... |
{"timestamp": "2025-07-18 12:07:29.533", "mode": "azero-full", "language": "en", "target": "en", "text": "excluding a one point four percent unfavorable impact from foreign exchange.", "text_tts": "int four percent unfavorable impact from foreign exchange", "translate": "excluding a one point four percent unfavorable i... |
{"timestamp": "2025-07-18 12:07:33.944", "mode": "azero-full", "language": "en", "target": "en", "text": "Adjusted gross margin was eighty four point one percent of sales,", "text_tts": "margin was eighty four point one percent of sales", "translate": "Adjusted gross margin was eighty four point one percent of sales,",... |
{"timestamp": "2025-07-18 12:07:44.084", "mode": "azero-full", "language": "en", "target": "en", "text": "adjusted R and D expense was fifteen point four percent of sales and adjusted SG and A expense was twenty four point six percent of sales.", "text_tts": "es and adjusted SG and A expense was twenty four point six p... |
{"timestamp": "2025-07-18 12:07:50.860", "mode": "azero-full", "language": "en", "target": "en", "text": "the adjusted operating margin ratio was forty two point three percent of sales.", "text_tts": "margin ratio was forty two point three percent of sales", "translate": "the adjusted operating margin ratio was forty t... |
{"timestamp": "2025-07-18 12:07:54.986", "mode": "azero-full", "language": "en", "target": "en", "text": "which includes a one point nine percent unfavorable impact", "text_tts": "a one point nine percent unfavorable impact", "translate": "which includes a one point nine percent unfavorable impact", "translate_tts": "w... |
{"timestamp": "2025-07-18 12:07:57.058", "mode": "azero-full", "language": "en", "target": "en", "text": "from acquired IPR and D expense.", "text_tts": "R and D expense", "translate": "from acquired IPR and D expense.", "translate_tts": "from acquired IPR and D expense", "is_final": false, "emotion": "", "events": "📞... |
{"timestamp": "2025-07-18 12:08:02.789", "mode": "azero-full", "language": "en", "target": "en", "text": "Net interest expense was six hundred twenty seven million dollars.", "text_tts": "was six hundred twenty seven million dollars", "translate": "Net interest expense was six hundred twenty seven million dollars.", "t... |
{"timestamp": "2025-07-18 12:08:05.613", "mode": "azero-full", "language": "en", "target": "en", "text": "The adjusted tax rate was fourteen point two percent.", "text_tts": "was fourteen point two percent", "translate": "The adjusted tax rate was fourteen point two percent.", "translate_tts": "The adjusted tax rate wa... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.